Transcript
Announcer:
You’re listening to NeuroFrontiers on ReachMD. On this episode, we’ll hear from Dr. Qihua Fan, who’s an Assistant Professor in the Department of Neurology at Virginia Commonwealth University in Richmond. She’ll be discussing approaches to inpatient myasthenia gravis treatment, which she spoke about at the AANEM 2026 Annual Meeting. Here’s Dr. Fan now.
Dr. Fan:
With the newer therapies that have evolved for myasthenia, the traditional treatment options for the inpatient side are evolving a little bit. So, while plasmapheresis, IVIG, and steroids remain the mainstay treatment options on the inpatient side, we have to think about if this inpatient rescue therapy makes sense with their outpatient longitudinal care plan.
So, for example, if somebody is on or is going to be on FcRn inhibitors outpatient, it might not make sense to put somebody on inpatient IVIG knowing that on the outpatient side, it's just going to get taken out by an FcRn inhibitor. And then, on the flip side, if you're planning to or you would like to put somebody on an FcRn inhibitor, it might make sense to see how patients do with plasmapheresis.
And so I think the main thing is, it's our job as neuromuscular doctors and treating physicians on the outpatient side for myasthenia patients to think through the contingency on inpatient admission plans, so that the admitting team—the general neurologist or neurohospitalist—can navigate the inpatient crisis treatment options a little bit easier and in a way that aligns with the outpatient longitudinal care plan.
Announcer:
That was Dr. Qihua Fan talking about considerations for inpatient myasthenia gravis treatment. To access this and other episodes in our series, visit NeuroFrontiers on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!
